Cell line · CVCL_1675
Papers34
1 to 20 of 34
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Stiffness-related stress granules promote the metastasis of early-stage oral squamous cell carcinoma via anoikis resistance. | Cell Oncol (Dordr) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ENOX2 (tNOX)-Associated Stemness in Oral Cancer Cells and Its Clinical Correlation in Head and Neck Tumors. | Antioxidants (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GSH as an A-A Type Allosteric Activator of PKM2: Modulating Cancer Cell Homeostasis and Ferroptosis Susceptibility. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Annexin A1-Targeted d-Peptide-Monomethyl Auristatin E Conjugate Enhanced Antitumor Effect of Monomethyl Auristatin E for Chemotherapy of Prostate Cancer. | Prostate | 2025 | Its Methods give the RRID and name the line | PubMed | |
| EGFRvIII-driven microenvironmental fibroblast activation and transformation accelerate oral cancer progression via lipocalin-2/STAT3 axis. | Neoplasia | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer. | NAR Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tribbles pseudokinase 3 drives cancer stemness in oral squamous cell carcinoma cells by supporting the expression levels of SOX2 and EGFR. | Int J Mol Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TNO155 is a selective SHP2 inhibitor to target PTPN11-dependent oral squamous cell carcinoma. | Heliyon | 2024 | Its Methods give the RRID and name the line | PubMed | |
| High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Hypoxia-Induced Long Noncoding RNA HIF1A-AS2 Regulates Stability of MHC Class I Protein in Head and Neck Cancer. | Cancer Immunol Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Integrative analysis reveals associations between oral microbiota dysbiosis and host genetic and epigenetic aberrations in oral cavity squamous cell carcinoma. | NPJ Biofilms Microbiomes | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Interplay of p62-mTORC1 and EGFR signaling promotes cisplatin resistance in oral cancer. | Heliyon | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic Targeting to Overcome Radioresistance in Head and Neck Cancer. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting tumor O-glycosylation modulates cancer-immune-cell crosstalk and enhances anti-PD-1 immunotherapy in head and neck cancer. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Prognosis of Midkine and AT1R expression in resectable head and neck squamous cell carcinoma. | Cancer Cell Int | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| DDX3 modulates the tumor microenvironment via its role in endoplasmic reticulum-associated translation. | iScience | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. | Elife | 2020 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1675/papers